Interferon-γ1b therapy in idiopathic pulmonary fibrosis: A metaanalysis

Ednan K. Bajwa, Najib T. Ayas, Michael Schuzer, Edwin Mak, Jay H. Ryu, Atul Malhotra

Research output: Contribution to journalArticle

46 Scopus citations

Abstract

Context: Despite the investigation of multiple therapeutic options, idiopathic pulmonary fibrosis (IPF) remains a devastating, progressively fatal disease. Much interest has focused on the use of interferon (IFN)-γ1b therapy, but the efficacy of this treatment has not been proven. Objective: To determine whether IFN treatment reduces mortality in patients with IPF. Design: A metaanalysis of randomized controlled trials evaluating the use of IFN-γ1b as treatment for IPF. Main outcome measure: Mortality in patients treated with IFN-γ1b was compared to mortality in patients treated with control therapies. Results: A total of three studies involving 390 patients was included in the analysis. IFN-γ1b therapy was associated with reduced mortality (hazard ratio [HR], 0.418; 95% confidence interval [CI], 0.253 to 0.690; p = 0.0003). A comparison of mortality at different time points revealed that IFN-γ1b therapy was associated with significantly reduced mortality at 1 year (0.0861; 95% CI, 0.0244 to 0.1478; p = 0.0063), 18 months (0.1682; 95% CI, 0.1065 to 0.2299; p < 0.0001), 650 days (0.1939; 95% CI, 0.1386 to 0.2492; p < 0.0001), and 2 years (0.2652; 95% CI, 0.1652 to 0.3652; p < 0.0001). Conclusion: When the results of multiple studies are combined in a metaanalysis, IFN-γ1b therapy is associated with reduced mortality.

Original languageEnglish (US)
Pages (from-to)203-206
Number of pages4
JournalChest
Volume128
Issue number1
DOIs
StatePublished - Jul 2005

Keywords

  • Interferon
  • Lung
  • Pulmonary fibrosis
  • Restriction
  • Survival
  • Treatment

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine
  • Critical Care and Intensive Care Medicine
  • Cardiology and Cardiovascular Medicine

Fingerprint Dive into the research topics of 'Interferon-γ1b therapy in idiopathic pulmonary fibrosis: A metaanalysis'. Together they form a unique fingerprint.

  • Cite this

    Bajwa, E. K., Ayas, N. T., Schuzer, M., Mak, E., Ryu, J. H., & Malhotra, A. (2005). Interferon-γ1b therapy in idiopathic pulmonary fibrosis: A metaanalysis. Chest, 128(1), 203-206. https://doi.org/10.1378/chest.128.1.203